CO6290771A2 - Composiciones y vacunas que comprenden una cantidad inmunogenica de una proteina o un fragmento e la misma que comprende una determinante antigenica de reactividad cruzada - Google Patents

Composiciones y vacunas que comprenden una cantidad inmunogenica de una proteina o un fragmento e la misma que comprende una determinante antigenica de reactividad cruzada

Info

Publication number
CO6290771A2
CO6290771A2 CO10119116A CO10119116A CO6290771A2 CO 6290771 A2 CO6290771 A2 CO 6290771A2 CO 10119116 A CO10119116 A CO 10119116A CO 10119116 A CO10119116 A CO 10119116A CO 6290771 A2 CO6290771 A2 CO 6290771A2
Authority
CO
Colombia
Prior art keywords
reactivity
compositions
cross
vaccines
determinant
Prior art date
Application number
CO10119116A
Other languages
English (en)
Inventor
Thomas Plocher
Manuel Campos
Richard Harland
Tood Johnson
Trent Harbison
Dan Keil
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40757034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6290771(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6290771A2 publication Critical patent/CO6290771A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/285—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)

Abstract

Se proporcionan composiciones y métodos para determinar moléculas reactivas cruzadas inmunológicamente que comprenden una determinante antigénica de reactividad cruzada, en particular para determinar proteínas que comprenden determinantes antigénicas de reactividad cruzada, en particular para determinar proteínas que tienen reactividad cruzada con base en selecciones serológicas usando pruebas inmunológicas secuenciales para un animal, incluyendo determinar las proteína de H. parasuis de reactividad cruzada. También se proporcionan composiciones, vacunas, y kits que usan las moléculas para diagnósticos y métodos para prevenir o tratar una enfermedad, trastorno, afección, o síntomas de la misma asociado con agentes infecciosos, en particular microorganismos infecciosos, en particular para prevenir o tratar una enfermedad, trastorno, afección, o síntoma de la misma asociado con infección por H. parasuis.
CO10119116A 2008-03-28 2010-09-27 Composiciones y vacunas que comprenden una cantidad inmunogenica de una proteina o un fragmento e la misma que comprende una determinante antigenica de reactividad cruzada CO6290771A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4026008P 2008-03-28 2008-03-28

Publications (1)

Publication Number Publication Date
CO6290771A2 true CO6290771A2 (es) 2011-06-20

Family

ID=40757034

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10119116A CO6290771A2 (es) 2008-03-28 2010-09-27 Composiciones y vacunas que comprenden una cantidad inmunogenica de una proteina o un fragmento e la misma que comprende una determinante antigenica de reactividad cruzada

Country Status (15)

Country Link
US (2) US9046528B2 (es)
EP (1) EP2262828B1 (es)
KR (1) KR101647159B1 (es)
CN (1) CN101981052B (es)
AR (1) AR071104A1 (es)
BR (1) BRPI0909493A2 (es)
CA (1) CA2719041C (es)
CL (1) CL2009000768A1 (es)
CO (1) CO6290771A2 (es)
ES (1) ES2551699T3 (es)
HK (1) HK1149770A1 (es)
MX (1) MX2010010614A (es)
PL (1) PL2262828T3 (es)
RU (1) RU2555530C2 (es)
WO (1) WO2009118273A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2262828T3 (pl) * 2008-03-28 2016-03-31 Elanco Tiergesundheit Ag Kompozycje, sposoby i zestawy
US20130039941A1 (en) * 2010-04-23 2013-02-14 Intervet International B.V. Vaccine comprising inactivated cells of haemophilus parasuis bacteria of serotype 5
CN102399724B (zh) * 2011-11-08 2013-01-02 山东省农业科学院畜牧兽医研究所 一种副猪嗜血杆菌lc株及其应用
CN104404056B (zh) * 2014-11-12 2017-07-18 四川农业大学 一种重组副猪嗜血杆菌免疫保护性抗原HbpA2及其制备方法
CN104306964B (zh) * 2014-11-12 2017-10-10 四川农业大学 重组副猪嗜血杆菌免疫保护性抗原HbpA2的用途及用其制备的亚单位疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713071B1 (en) * 1998-10-22 2004-03-30 Pfizer Inc. Proteins from actinobacillus pleuropneumoniae
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
RU2268933C1 (ru) * 2004-04-21 2006-01-27 Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ ВНИИЗЖ) ШТАММ Haemophilus parasuis СК-1 - ВОЗБУДИТЕЛЬ ГЕМОФИЛЕЗНОГО ПОЛИСЕРОЗИТА СВИНЕЙ ДЛЯ ИЗГОТОВЛЕНИЯ ДИАГНОСТИЧЕСКИХ И ВАКЦИННЫХ ПРЕПАРАТОВ
WO2006132893A2 (en) * 2005-06-07 2006-12-14 Buck Institute For Age Research Sialic acid abc transporters in prokaryotes therapeutic targets
PL2262828T3 (pl) * 2008-03-28 2016-03-31 Elanco Tiergesundheit Ag Kompozycje, sposoby i zestawy
BR112012011598A2 (pt) * 2009-11-04 2016-06-28 Univ Minnesota polipeptídeos de haemophilus parasuis e métodos de uso

Also Published As

Publication number Publication date
US20110014225A1 (en) 2011-01-20
US20150293118A1 (en) 2015-10-15
EP2262828B1 (en) 2015-09-30
KR20100139096A (ko) 2010-12-31
KR101647159B1 (ko) 2016-08-09
CA2719041C (en) 2016-08-16
CL2009000768A1 (es) 2011-07-01
RU2010143903A (ru) 2012-05-10
EP2262828A1 (en) 2010-12-22
MX2010010614A (es) 2010-11-09
AR071104A1 (es) 2010-05-26
CN101981052A (zh) 2011-02-23
US9046528B2 (en) 2015-06-02
WO2009118273A1 (en) 2009-10-01
RU2555530C2 (ru) 2015-07-10
CA2719041A1 (en) 2009-10-01
PL2262828T3 (pl) 2016-03-31
CN101981052B (zh) 2014-11-26
HK1149770A1 (en) 2011-10-14
US10261092B2 (en) 2019-04-16
BRPI0909493A2 (pt) 2017-11-07
ES2551699T3 (es) 2015-11-23

Similar Documents

Publication Publication Date Title
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
NO20072253L (no) Forbedrede vaksiner
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
CO6290771A2 (es) Composiciones y vacunas que comprenden una cantidad inmunogenica de una proteina o un fragmento e la misma que comprende una determinante antigenica de reactividad cruzada
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
RU2017123262A (ru) Иммуногенные композиции для применения в пневмококковых вакцинах
AR054474A1 (es) Formulacion de anticuerpos estables
CY1116488T1 (el) Αντισωματα anti-προπερδινης
RS53215B (en) NEUTRAL ANTIBODIES HAVING SPECIFICITY TO HUMAN IL-17
CY1118153T1 (el) Αγωγη μικροβιακων μολυνσεων
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
CR20110091A (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
CY1112920T1 (el) Σχηματα ανοσοποιησης με συζευγματα μηνιγγιτιδοκοκκου
CR11783A (es) Molecula de union al antigeno capaz de unirse repetidamente a dos o mas moleculas de antigeno
AR078423A1 (es) Vacunas dirigidas a las celulas de langerhans
AR077611A1 (es) Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso.
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
BR112013027867A2 (pt) "método de detectar o nível de um anticorpo anti-ip10 em amostra, anticorpo monoclonal isolado ou porção de ligação de antígeno do mesmo, linhagem de célula de hibridoma e kit"
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
CY1110948T1 (el) Μεθοδος διαγνωσης lawsonia intracellularis
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
EA202192606A1 (ru) Антитела к пироглутамат--амилоиду и их применение

Legal Events

Date Code Title Description
FG Application granted